Summary of NPCR-CSS Changes: Diagnosis Years 2017-2020

Attachment 3b

Summary of Changes to NPCR CSS Submission Specifications from Diagnosis Year 2017 to 2020

Modified Submission Practices:

• Record layout format changes as data items are added or removed from collection requirements and as improvements are made to data transmission methods. To accommodate these changes, the NPCR CSS submission files are updated to the XML format.

• NPCR CSS data items list is updated to remove information no longer relevant to analytic processes. These changes include various geographic and extent of disease information.

Rural-Urban Continuum/Beale Code 1993

Census Tract 1970/80/90

Census Cod Sys 1970/80/90

Census Tr Cert 1970/80/90

County at DX GeoCode 1970/80/90

Census Tr Cert 1970/80/90

TNM Path T

TNM Path N

TNM Path M

TNM Path Stage Group

TNM Path Descriptor

TNM Clin T

TNM Clin N

TNM Clin M

TNM Clin Stage Group

TNM Clin Descriptor

NPCR Derived Clin Stage Group

NPCR Derived Path Stage Group

CS Extension

CS Tumor Size/Ext Eval

CS Lymph Nodes

CX Lymph Nodes Eval

CS Mets at DX

CS Mets Eval

CS Version Input Current

Derived AJCC-6 Stage Grp

Derived AJCC-7 Stage Grp

CS Site-Specific Factor 1 for C34 (lung), C384 (pleura), C692 (retinoblastoma), C619 (prostate)

CS Site-Specific Factor 2 for C54 and C55 (corpus uteri)

CS Site-Specific Factor 3 for C619 (prostate)

CS Site-Specific Factor 8 for C50 (breast)

CS Site-Specific Factor 9 for C50 (breast)

CS Site-Specific Factor 11 for C50 (breast)

CS Site-Specific Factor 13 for C50 (breast)

CS Site-Specific Factor 14 for C50 (breast)

CS Site-Specific Factor 25

New Variables:

• NPCR CSS data items list is updated to include information determined to be relevant to current analytic processes. These changes include information about the reporting source, demographic characteristics, tumor or extent of disease characteristics, and survival. Some information is derived using electronic algorithms with no additional workload from the respondents. The remaining information is routinely collected by respondents adding no additional workload.

CoC Accredited Flag

Race 3

Race 4

Race 5

2018-2019 Congressional Districts (tract-based) [derived]

EPHT Sub-County Areas (tract-based) [derived]

Phase I Radiation Treatment Modality

SEER Summary Stage 2018

Schema ID [derived]

Schema Discriminator 1 [derived]

Schema Discriminator 2 [derived]

AJCC ID [derived]

Grade Clinical

Grade Pathological

Grade Post Therapy

Brain Molecular Markers

Estrogen Receptor Summary

HER2 Overall Summary

Progesterone Receptor Summary

PSA (Prostatic Specific Antigen) Lab Value

Breslow Tumor Thickness

RX Date Mst Defn Srg

RX Date Mst Defn Srg Flag

RX Date Surgery

RX Date Surgery Flag

Rx Summ—Surg Primary Site

Rx Summ—Scope Reg LN Sur

Rx Summ—Surg Oth Reg/Dis

Reason for No Surgery

RX Date Radiation

RX Date Radiation Flag

RX Summ—Radiation

RX Summ—Surg/Rad Seq

Reason for No Radiation

RX Date Chemo

RX Date Chemo Flag

Rx Summ—Chemo

RX Date Hormone

RX Date Hormone Flag

Rx Summ—Hormone

RX Date BRM

RX Date BRM Flag

Rx Summ—BRM

RX Date Other

RX Date Other Flag

Vital Status Recode [derived]

Record Number Recode [derived]

Surv-Date Active Followup [derived]

Surv-Flag Active Followup [derived]

Surv-Date Presumed Alive [derived]

Surv-Flag Presumed Alive [derived]

Surv-Date Dx Recode [derived]

SEER Cause-Specific COD [derived]

SEER Other COD [derived]